GH Research opened lower at $19.01, compared with its previous close of $19.25. In the last trading session, the stock traded between $17.96 and $19.09. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in GH Research is now worth
$ 80.67
Resulting in a loss of
$ 19.33 (19.33%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.76 (-3.95%)
Day High
$19.09
Day Low
$17.96
Day Open
$19.01
Prev Close
$19.25
Volume
1,70,215
1W Return
-7.43%
1M Return
-8.13%
3M Return
-36.60%
6M Return
-13.03%
1Y Return
30.03%
Fundamentals
Market Cap ($ Mn)
1,269
PE Ratio
-
PB Ratio
5.32
PEG Ratio
-
ROE
-17.70%
ROCE
-19.53%
EPS (TTM)
$-0.22
Investment Returns
1 Week
-7.43%
1 Month
-8.13%
3 Months
-36.60%
6 Months
-13.03%
9 Months
22.05%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
6Aug
GH Research Q2 Results: EPS beats estimate, losses widen YoY
GH Research posted Q2 EPS of $(0.23), beating the $(0.30) analyst estimate by 23.33%. However, this represents a 53.33% widening of losses compared to $(0.15) per share in the same period last year, highlighting deteriorating year-over-year performance despite meeting short-term market expectations.
3mo ago
17Jul
GH Research shares rise 11.40% on Eli Lilly deal news
GH Research PLC shares rose 11.40% to $29.99 on Thursday following Eli Lilly and Co.'s agreement to acquire AtaiBeckley Inc for up to $3.80 billion. The deal highlights sector interest in psychedelic therapies, where GH Research's GH001 targets treatment-resistant depression. Recent Phase 2b data showed Day 8 remission rates of 53.9%-63.6%, and the FDA lifted a clinical hold on the IND in January.
